Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boehringer Ingelheim’s Dabigatran Demonstrates Non-Inferiority To Lovenox

This article was originally published in The Pink Sheet Daily

Executive Summary

The drug maker is in discussions with U.S. regulators regarding submission for venous thromboembolism, but has not released a filing timeline.

You may also be interested in...



Heart Attack Signal Is Likely Focus For Panel Review Of Boehringer Ingelheim's Pradaxa

When FDA's Cardiovascular and Renal Drugs Advisory Committee meets Sept. 20 to consider Boehringer Ingelheim's Pradaxa (dabigatran) for stroke prevention, a significantly higher rate of heart attacks among clinical trial patients compared with warfarin is likely to come up.

Heart Attack Signal Is Likely Focus For Panel Review Of Boehringer Ingelheim's Pradaxa

When FDA's Cardiovascular and Renal Drugs Advisory Committee meets Sept. 20 to consider Boehringer Ingelheim's Pradaxa (dabigatran) for stroke prevention, a significantly higher rate of heart attacks among clinical trial patients compared with warfarin is likely to come up.

Atrial Fibrillation Data For Boehringer Ingelheim’s Dabigatran Due In Early 2009

Firm completes enrollment in RE-LY trial, one of seven in the Phase III RE-VOLUTION program for the investigational antithrombotic.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066296

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel